APAC / Issue 3 2018 5 NEWS , Hyland Healthcare is a part of Hyland, a leader in providing software solutions for managing con- tent, processes and cases for organizations across the globe. For over 25 years, Hyland has enabled more than 19,000 or- ganizations to digitalize their workplaces and fundamentally transform their operations. Recently, the leader in in provid- ing software solutions for man- aging content, processes and cases, Hyland Healthcare, has appointed two new sales manag- ers in the Asia Pacific (APAC) re- gion. Peter Weston joins Hyland as the manager of healthcare sales in the region, and Christine Lugg is the new industry manager of international healthcare at Hy- land. Peter Weston, an Australian na- tional, has more than 20 years of experience in the software and healthcare industries across the Asia Pacific region. He comes to Hyland from IBM Watson Health Imaging where served as the re- gional sales manager. His tech expertise combined with an early career as an epidemiologist, as well as his familiarity with the ter- ritory, make Peter an ideal fit. Christine Lugg, based in South Australia, brings more than 15 years of sales experience devel- oping successful partnerships across the health, education, employment and welfare sectors. Having previously worked for Hyland’s partner, Iron Mountain, Lugg’s industry expertise will help Hyland grow its customer base in the region. “Peter and Christine will be tre- mendous assets to the Hyland Healthcare team. They bring deep expertise and relationships within the APAC region, which remains an important growth market for Hyland,” said Susan deCathelineau, vice president of global healthcare sales and ser- vices at Hyland. “We are thrilled to fill these roles with talented people from within the region as we work to be the leading provid- er of content services worldwide.” Hyland Healthcare Expands Sales Leadership in Asia Pacific Region Hyland appoints Australians PeterWeston and Christine Lugg to new sales leadership roles. On the 7th March 2018, ProSciento, Inc., a full scope clin- ical R&D services provider focused ex- clusively on early phase clinical development programs in met- abolic diseases, announced the expansion of its Asia Pacific oper- ations with an office in Brisbane, Queensland, Australia. The office will provide functional services in regulatory affairs, clin- ical project management, clinical monitoring, and medical affairs and provide third-party vendor management support for ProSci- ento’s global biopharma clients. ProSciento’s clinical trial site net- work and the number of specialty methods and imaging hubs in that region is growing steadily. The country is recognized for its ma- ture clinical research and health- care infrastructure, highly skilled researchers, and a streamlined regulatory process, all key factors to support quality and expedien- cy in early phase clinical trials. Data from studies conducted in Australia can be used to support international regulatory applica- tions, including the US FDA and European Medicines Evaluation Agency (EMEA). Furthermore, the Australian government offers R&D tax incentives that make it a cost-effective location to carry out clinical trials. “For many of our clients, Austral- ia is a requested location for early phase clinical trials, often as part of a global multi-site clinical study strategy. The proximity to Asia and the Indian sub-continent, with many of the emerging biopharma companies situated in those ge- ographies, makes Australia an excellent location for organizations like ProSciento. We have found an extraordinary commitment to the highest scientific and opera- tional quality standards and many centres with advanced metabolic research expertise, all of which are a natural fit with ProSciento’s mission and vision. We’re very pleased to be expanding our op- erations in that region to further serve our clients’ needs globally,” said Marcus Hompesch, M.D., ProSciento’s Chief Executive Of- ficer.